Analyst downgrades typically lead to a negative short-term impact on the stock price as they may reflect a less optimistic outlook on the company's future performance. Given the downgrade from Buy to Neutral, it suggests a shift towards a more cautious stance on Spruce Biosciences by the analyst, which could influence investor sentiment and lead to a decrease in stock price.